{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:58:04Z","timestamp":1788307084290,"version":"build-2803163510"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,8]]},"DOI":"10.7759\/cureus.57860","type":"journal-article","created":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T23:10:55Z","timestamp":1712617855000},"source":"Crossref","is-referenced-by-count":5,"title":["Increased Age-Adjusted Cancer Mortality After the Third mRNA-Lipid Nanoparticle Vaccine Dose During the COVID-19 Pandemic in Japan"],"prefix":"10.7759","author":[{"given":"Miki","family":"Gibo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"COVID-19 vaccines. (2023). Accessed. February 29, 2024: https:\/\/japan.kantei.go.jp\/ongoingtopics\/vaccine.html."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05522-2","article-title":"The WHO estimates of excess mortality associated with the COVID-19 pandemic","volume":"613","author":"Msemburi W","year":"2023","unstructured":"Msemburi W, Karlinsky A, Knutson V, Aleshin-Guendel S, Chatterji S, Wakefield J. The WHO estimates of excess mortality associated with the COVID-19 pandemic. Nature. 2023, 613:130-7. 10.1038\/s41586-022-05522-2","journal-title":"Nature"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02796-3","article-title":"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21","volume":"399","author":"COVID-19 Excess Mortality Collaborators","year":"2022","unstructured":"COVID-19 Excess Mortality Collaborators. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21. Lancet. 2022, 399:1513-36. 10.1016\/S0140-6736(21)02796-3","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1137","article-title":"Excess deaths associated with covid-19 pandemic in 2020: age and sex disaggregated time series analysis in 29 high income countries","volume":"613","author":"Msemburi W","year":"2023","unstructured":"Msemburi W, Karlinsky A, Knutson V, Aleshin-Guendel S, Chatterji S, Wakefield J. Excess deaths associated with covid-19 pandemic in 2020: age and sex disaggregated time series analysis in 29 high income countries. Nature. 2023, 613:130-7. 10.1136\/bmj.n1137","journal-title":"Nature"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.33425\/2690-5191.1077","article-title":"Annual all-cause mortality rate in Germany and Japan (2005 to 2022) with focus on the COVID-19 pandemic: hypotheses and trend analyses","volume":"5","author":"Scherb H","year":"2023","unstructured":"Scherb H, Hayashi K. Annual all-cause mortality rate in Germany and Japan (2005 to 2022) with focus on the COVID-19 pandemic: hypotheses and trend analyses. Med Clin Sci. 2023, 5:16-22. 10.33425\/2690-5191.1077","journal-title":"Med Clin Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.39371","article-title":"Estimation of excess mortality in Germany during 2020-2022","volume":"15","author":"Kuhbandner C","year":"2023","unstructured":"Kuhbandner C, Reitzner M. Estimation of excess mortality in Germany during 2020-2022. Cureus. 2023, 15:e39371. 10.7759\/cureus.39371","journal-title":"Cureus"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30388-0","article-title":"The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study","volume":"21","author":"Maringe C","year":"2020","unstructured":"Maringe C, Spicer J, Morris M, et al.. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol. 2020, 21:1023-34. 10.1016\/S1470-2045(20)30388-0","journal-title":"Lancet Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djab097","article-title":"Impact of the COVID-19 pandemic on breast cancer mortality in the US: estimates from collaborative simulation modeling","volume":"113","author":"Alagoz O","year":"2021","unstructured":"Alagoz O, Lowry KP, Kurian AW, et al.. Impact of the COVID-19 pandemic on breast cancer mortality in the US: estimates from collaborative simulation modeling. J Natl Cancer Inst. 2021, 113:1484-94. 10.1093\/jnci\/djab097","journal-title":"J Natl Cancer Inst"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-21-0230","article-title":"Excess mortality in a nationwide cohort of cancer patients during the initial phase of the COVID-19 pandemic in Belgium","volume":"30","author":"Silversmit G","year":"2021","unstructured":"Silversmit G, Verdoodt F, Van Damme N, De Schutter H, Van Eycken L. Excess mortality in a nationwide cohort of cancer patients during the initial phase of the COVID-19 pandemic in Belgium. Cancer Epidemiol Biomarkers Prev. 2021, 30:1615-9. 10.1158\/1055-9965.EPI-21-0230","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39322-7","article-title":"Attributed causes of excess mortality during the COVID-19 pandemic in a south Indian city","volume":"14","author":"Lewnard JA","year":"2023","unstructured":"Lewnard JA, B CM, Kang G, Laxminarayan R. Attributed causes of excess mortality during the COVID-19 pandemic in a south Indian city. Nat Commun. 2023, 14:3563. 10.1038\/s41467-023-39322-7","journal-title":"Nat Commun"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-071785","article-title":"Impact of the COVID-19 pandemic on mortality trends in Japan: a reversal in 2021? A descriptive analysis of national mortality data, 1995-2021","volume":"13","author":"Tanaka H","year":"2023","unstructured":"Tanaka H, Togawa K, Katanoda K. Impact of the COVID-19 pandemic on mortality trends in Japan: a reversal in 2021? A descriptive analysis of national mortality data, 1995-2021. BMJ Open. 2023, 13:e071785. 10.1136\/bmjopen-2023-071785","journal-title":"BMJ Open"},{"key":"ref12","unstructured":"Excess and exiguous deaths dashboard in Japan. (2023). Accessed. March 28, 2024: https:\/\/exdeaths-japan.org\/en\/."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2188\/jea.JE201500","article-title":"Accuracy of death certificates and assessment of factors for misclassification of underlying cause of death","volume":"26","author":"Mieno MN","year":"2016","unstructured":"Mieno MN, Tanaka N, Arai T, Kawahara T, Kuchiba A, Ishikawa S, Sawabe M. Accuracy of death certificates and assessment of factors for misclassification of underlying cause of death. J Epidemiol. 2016, 26:191-8. 10.2188\/jea.JE201500","journal-title":"J Epidemiol"},{"key":"ref14","unstructured":"[The Ministry of Health, Labour and Welfare. e-Stat, The Vital Statistics]. (2023). Accessed: March 28, 2024: https:\/\/www.e-stat.go.jp\/stat-search\/files?page=1&layout=datalist&toukei=00450011&tstat=000001028897&cycle=1&tclass1=...."},{"key":"ref15","unstructured":"[The Statistics Bureau of the Ministry of Internal Affairs and Communications. the summary of population estimation results]. (2023). Accessed: March 28, 2024: https:\/\/www.stat.go.jp\/data\/jinsui\/2.html#monthly."},{"key":"ref16","unstructured":"[Visualizing the data, information on COVID-19 infections]. (2023). Accessed. March 28, 2024: https:\/\/covid19.mhlw.go.jp\/extensions\/public\/en\/index.html."},{"key":"ref17","unstructured":"[Status of reports of suspected adverse reactions from medical institutions under the immunization law]. (2023). Accessed. March 28, 2024: https:\/\/www.mhlw.go.jp\/content\/10601000\/001068689.pdf."},{"key":"ref18","unstructured":"Finding and using health statistics. (2023). Accessed. March 10, 2024: https:\/\/www.nlm.nih.gov\/oet\/ed\/stats\/02-600.html#:~:text=Age%2Dadjusted%20rates%20were%20calculated,size%20of%20that%...."},{"key":"ref19","unstructured":"[The standard population for age-adjusted mortality rates]. (2020). Accessed. March 28, 2024: https:\/\/www.mhlw.go.jp\/toukei\/saikin\/hw\/jinkou\/kakutei20\/dl\/14_nencho.pdf."},{"key":"ref20","unstructured":"[Sex-specific smoothed standard population dataset]. (2019). Accessed. March 28, 2024: https:\/\/www.mhlw.go.jp\/content\/10700000\/000557741.pdf."},{"key":"ref21","unstructured":"Cumulative confirmed COVID-19 deaths per million people. (2020). Accessed. March 11, 2024: https:\/\/ourworldindata.org\/explorers\/coronavirus-data-explorer?tab=table&zoomToSelection=true&time=2020-12-31..latest...."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1200\/GO.20.00471","article-title":"Reduction in the number of procedures and hospitalizations and increase in cancer mortality during the COVID-19 pandemic in Brazil","volume":"7","author":"Fonseca GA","year":"2021","unstructured":"Fonseca GA, Normando PG, Loureiro LV, Rodrigues RE, Oliveira VA, Melo MD, Santana IA. Reduction in the number of procedures and hospitalizations and increase in cancer mortality during the COVID-19 pandemic in Brazil. JCO Glob Oncol. 2021, 7:4-9. 10.1200\/GO.20.00471","journal-title":"JCO Glob Oncol"},{"key":"ref23","unstructured":"[Impact of new coronavirus infection on cancer screening and treatment (evaluation in FY2021)]. (2023). Accessed. March 28, 2024: https:\/\/www.mhlw.go.jp\/content\/10901000\/001046961.pdf."},{"key":"ref24","unstructured":"[In-Hospital Cancer Registry. 2022 National Aggregate]. (2024). Accessed: February 28, 2024: https:\/\/ganjoho.jp\/public\/qa_links\/report\/hosp_c\/pdf\/2022_report.pdf."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.56098\/ijvtpr.v2i1.23","article-title":"Worse than the disease? Reviewing some possible unintended consequences of the mRNA vaccines against COVID-19","volume":"2","author":"Seneff S","year":"2021","unstructured":"Seneff S, Nigh G. Worse than the disease? Reviewing some possible unintended consequences of the mRNA vaccines against COVID-19. Int J Vaccine, theory, Pract Res. 2021, 2:38-79. 10.56098\/ijvtpr.v2i1.23","journal-title":"Int J Vaccine, theory, Pract Res"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2022.113008","article-title":"Innate immune suppression by SARS-CoV-2 mRNA vaccinations: the role of G-quadruplexes, exosomes, and MicroRNAs","volume":"164","author":"Seneff S","year":"2022","unstructured":"Seneff S, Nigh G, Kyriakopoulos AM, McCullough PA. Innate immune suppression by SARS-CoV-2 mRNA vaccinations: the role of G-quadruplexes, exosomes, and MicroRNAs. Food Chem Toxicol. 2022, 164:113008. 10.1016\/j.fct.2022.113008","journal-title":"Food Chem Toxicol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11082287","article-title":"\u2018Spikeopathy\u2019: COVID-19 spike protein is pathogenic, from both virus and vaccine mRNA","volume":"11","author":"Parry PI","year":"2023","unstructured":"Parry PI, Lefringhausen A, Turni C, Neil CJ, Cosford R, Hudson NJ, Gillespie J. \u2018Spikeopathy\u2019: COVID-19 spike protein is pathogenic, from both virus and vaccine mRNA. Biomedicines. 2023, 11:2287. 10.3390\/biomedicines11082287","journal-title":"Biomedicines"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.50703","article-title":"SARS-CoV-2 vaccination and the multi-hit hypothesis of oncogenesis","volume":"15","author":"Valdes Angues R","year":"2023","unstructured":"Valdes Angues R, Perea Bustos Y. SARS-CoV-2 vaccination and the multi-hit hypothesis of oncogenesis. Cureus. 2023, 15:e50703. 10.7759\/cureus.50703","journal-title":"Cureus"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.798095","article-title":"Rapid progression of angioimmunoblastic T cell lymphoma following BNT162b2 mRNA vaccine booster shot: a case report","volume":"8","author":"Goldman S","year":"2021","unstructured":"Goldman S, Bron D, Tousseyn T, et al.. Rapid progression of angioimmunoblastic T cell lymphoma following BNT162b2 mRNA vaccine booster shot: a case report. Front Med (Lausanne). 2021, 8:798095. 10.3389\/fmed.2021.798095","journal-title":"Front Med (Lausanne)"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.963393","article-title":"Rapid progression of marginal zone B-cell lymphoma after COVID-19 vaccination (BNT162b2): a case report","volume":"9","author":"Sekizawa A","year":"2022","unstructured":"Sekizawa A, Hashimoto K, Kobayashi S, et al.. Rapid progression of marginal zone B-cell lymphoma after COVID-19 vaccination (BNT162b2): a case report. Front Med (Lausanne). 2022, 9:963393. 10.3389\/fmed.2022.963393","journal-title":"Front Med (Lausanne)"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58070874","article-title":"Hematologic malignancies diagnosed in the context of the mRNA COVID-19 vaccination campaign: a report of two cases","volume":"58","author":"Zamfir MA","year":"2022","unstructured":"Zamfir MA, Moraru L, Dobrea C, et al.. Hematologic malignancies diagnosed in the context of the mRNA COVID-19 vaccination campaign: a report of two cases. Medicina (Kaunas). 2022, 58:874. 10.3390\/medicina58070874","journal-title":"Medicina (Kaunas)"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59010157","article-title":"Non-Hodgkin lymphoma developed shortly after mRNA COVID-19 vaccination: report of a case and review of the literature","volume":"59","author":"Cavanna L","year":"2023","unstructured":"Cavanna L, Grassi SO, Ruffini L, et al.. Non-Hodgkin lymphoma developed shortly after mRNA COVID-19 vaccination: report of a case and review of the literature. Medicina (Kaunas). 2023, 59:157. 10.3390\/medicina59010157","journal-title":"Medicina (Kaunas)"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59030627","article-title":"pH-positive B-cell acute lymphoblastic leukemia occurring after receipt of bivalent SARS-CoV-2 mRNA vaccine booster: a case report","volume":"59","author":"Ang SY","year":"2023","unstructured":"Ang SY, Huang YF, Chang CT. pH-positive B-cell acute lymphoblastic leukemia occurring after receipt of bivalent SARS-CoV-2 mRNA vaccine booster: a case report. Medicina (Kaunas). 2023, 59:627. 10.3390\/medicina59030627","journal-title":"Medicina (Kaunas)"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.17179\/excli2023-6145","article-title":"Bell's palsy or an aggressive infiltrating basaloid carcinoma post-mRNA vaccination for COVID-19? A case report and review of the literature","volume":"22","author":"Kyriakopoulos AM","year":"2023","unstructured":"Kyriakopoulos AM, Nigh G, McCullough PA, Olivier MD, Seneff S. Bell's palsy or an aggressive infiltrating basaloid carcinoma post-mRNA vaccination for COVID-19? A case report and review of the literature. EXCLI J. 2023, 22:992-1011. 10.17179\/excli2023-6145","journal-title":"EXCLI J"},{"key":"ref35","unstructured":"Number of mRNA molecules in Pfizer Biontec COVID-19 vaccine. (2021). Accessed. March 28, 2024: https:\/\/ameblo.jp\/toonomikado\/entry-12667109507.html."},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.31219\/osf.io\/bcsa6","article-title":"Differences in vaccine and SARS-CoV-2 replication derived mRNA: implications for cell biology and future disease [PREPRINT]","author":"McKernan K","year":"2021","unstructured":"McKernan K, Kyriakopoulos A, McCullough PA. Differences in vaccine and SARS-CoV-2 replication derived mRNA: implications for cell biology and future disease [PREPRINT]. OSF Preprints. 2021, 10.31219\/osf.io\/bcsa6","journal-title":"OSF Preprints"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3109\/03014460.2013.807878","article-title":"An estimation of the number of cells in the human body","volume":"40","author":"Bianconi E","year":"2013","unstructured":"Bianconi E, Piovesan A, Facchin F, et al.. An estimation of the number of cells in the human body. Ann Hum Biol. 2013, 40:463-71. 10.3109\/03014460.2013.807878","journal-title":"Ann Hum Biol"},{"key":"ref38","unstructured":"SARS-CoV-2 mRNA vaccine (BNT162, PF-07302048). (2021). Accessed. March 28, 2024: https:\/\/www.pmda.go.jp\/drugs\/2021\/P20210212001\/672212000_30300AMX00231_I100_2.pdf."},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.01.018","article-title":"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination","volume":"185","author":"R\u00f6ltgen K","year":"2022","unstructured":"R\u00f6ltgen K, Nielsen SC, Silva O, et al.. Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination. Cell. 2022, 185:1025-40.e14. 10.1016\/j.cell.2022.01.018","journal-title":"Cell"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1007\/s13273-021-00171-4","article-title":"Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency","volume":"18","author":"Kim SC","year":"2022","unstructured":"Kim SC, Sekhon SS, Shin WR, Ahn G, Cho BK, Ahn JY, Kim YH. Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency. Mol Cell Toxicol. 2022, 18:1-8. 10.1007\/s13273-021-00171-4","journal-title":"Mol Cell Toxicol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2100637","article-title":"Cutting edge: Circulating exosomes with Covid spike protein are induced by BNT162b2 (Pfizer-BioNTech) vaccination prior to development of antibodies: a novel mechanism for immune activation by mRNA vaccines","volume":"207","author":"Bansal S","year":"2021","unstructured":"Bansal S, Perincheri S, Fleming T, Poulson C, Tiffany B, Bremner RM, Mohanakumar T. Cutting edge: Circulating exosomes with Covid spike protein are induced by BNT162b2 (Pfizer-BioNTech) vaccination prior to development of antibodies: a novel mechanism for immune activation by mRNA vaccines. J Immunol. 2021, 207:2405-10. 10.4049\/jimmunol.2100637","journal-title":"J Immunol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1002\/prca.202300048","article-title":"Detection of recombinant Spike protein in the blood of individuals vaccinated against SARS-CoV-2: possible molecular mechanisms","volume":"17","author":"Brogna C","year":"2023","unstructured":"Brogna C, Cristoni S, Marino G, et al.. Detection of recombinant Spike protein in the blood of individuals vaccinated against SARS-CoV-2: possible molecular mechanisms. Proteomics Clin Appl. 2023, 17:e2300048. 10.1002\/prca.202300048","journal-title":"Proteomics Clin Appl"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.12688\/wellcomeopenres.16002.2","article-title":"SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus","volume":"5","author":"Andersson MI","year":"2020","unstructured":"Andersson MI, Arancibia-Carcamo CV, Auckland K, et al.. SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus. Wellcome Open Res. 2020, 5:181. 10.12688\/wellcomeopenres.16002.2","journal-title":"Wellcome Open Res"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2196-x","article-title":"Virological assessment of hospitalized patients with COVID-2019","volume":"581","author":"W\u00f6lfel R","year":"2020","unstructured":"W\u00f6lfel R, Corman VM, Guggemos W, et al.. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020, 581:465-9. 10.1038\/s41586-020-2196-x","journal-title":"Nature"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/hvaa213","article-title":"Ultra-sensitive serial profiling of SARS-CoV-2 antigens and antibodies in plasma to understand disease progression in COVID-19 patients with severe disease","volume":"66","author":"Ogata AF","year":"2020","unstructured":"Ogata AF, Maley AM, Wu C, et al.. Ultra-sensitive serial profiling of SARS-CoV-2 antigens and antibodies in plasma to understand disease progression in COVID-19 patients with severe disease. Clin Chem. 2020, 66:1562-72. 10.1093\/clinchem\/hvaa213","journal-title":"Clin Chem"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad209","article-title":"Effectiveness of the coronavirus disease 2019 bivalent vaccine","volume":"10","author":"Shrestha NK","year":"2023","unstructured":"Shrestha NK, Burke PC, Nowacki AS, Simon JF, Hagen A, Gordon SM. Effectiveness of the coronavirus disease 2019 bivalent vaccine. Open Forum Infect Dis. 2023, 10:ofad209. 10.1093\/ofid\/ofad209","journal-title":"Open Forum Infect Dis"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.05.032","article-title":"An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies","volume":"184","author":"Liu Y","year":"2021","unstructured":"Liu Y, Soh WT, Kishikawa JI, et al.. An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies. Cell. 2021, 184:3452-66.e18. 10.1016\/j.cell.2021.05.032","journal-title":"Cell"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2017.04.008","article-title":"Original antigenic sin: a comprehensive review","volume":"83","author":"Vatti A","year":"2017","unstructured":"Vatti A, Monsalve DM, Pacheco Y, Chang C, Anaya JM, Gershwin ME. Original antigenic sin: a comprehensive review. J Autoimmun. 2017, 83:12-21. 10.1016\/j.jaut.2017.04.008","journal-title":"J Autoimmun"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13596","article-title":"Update on guidelines for the management of cancer-associated thrombosis","volume":"26","author":"Streiff MB","year":"2021","unstructured":"Streiff MB, Abutalib SA, Farge D, Murphy M, Connors JM, Piazza G. Update on guidelines for the management of cancer-associated thrombosis. Oncologist. 2021, 26:e24-40. 10.1002\/onco.13596","journal-title":"Oncologist"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.10.021","article-title":"Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases","volume":"49","author":"Walker AJ","year":"2013","unstructured":"Walker AJ, Card TR, West J, Crooks C, Grainge MJ. Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases. Eur J Cancer. 2013, 49:1404-13. 10.1016\/j.ejca.2012.10.021","journal-title":"Eur J Cancer"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.2491\/jjsth.34.556","article-title":"[Reviews: cancer-associated thrombosis: crosstalk between cancer and blood coagulation-fibrinolysis system]","volume":"34","author":"Madoiwa S","year":"2023","unstructured":"Madoiwa S. [Reviews: cancer-associated thrombosis: crosstalk between cancer and blood coagulation-fibrinolysis system]. Nihon Kessen Shiketsu Gakkai Shi. 2023, 34:556-65. 10.2491\/jjsth.34.556","journal-title":"Nihon Kessen Shiketsu Gakkai Shi"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1687890","article-title":"Disseminated intravascular coagulation in cancer: an update","volume":"45","author":"Levi M","year":"2019","unstructured":"Levi M. Disseminated intravascular coagulation in cancer: an update. Semin Thromb Hemost. 2019, 45:342-7. 10.1055\/s-0039-1687890","journal-title":"Semin Thromb Hemost"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232415480","article-title":"SARS-CoV-2 spike protein induces hemagglutination: implications for COVID-19 morbidities and therapeutics and for vaccine adverse effects","volume":"23","author":"Boschi C","year":"2022","unstructured":"Boschi C, Scheim DE, Bancod A, et al.. SARS-CoV-2 spike protein induces hemagglutination: implications for COVID-19 morbidities and therapeutics and for vaccine adverse effects. Int J Mol Sci. 2022, 23:15480. 10.3390\/ijms232415480","journal-title":"Int J Mol Sci"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009128","article-title":"SARS-CoV-2 spike protein promotes IL-6 trans-signaling by activation of angiotensin II receptor signaling in epithelial cells","volume":"16","author":"Patra T","year":"2020","unstructured":"Patra T, Meyer K, Geerling L, et al.. SARS-CoV-2 spike protein promotes IL-6 trans-signaling by activation of angiotensin II receptor signaling in epithelial cells. PLoS Pathog. 2020, 16:10.1371\/journal.ppat.1009128","journal-title":"PLoS Pathog"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2020.106823","article-title":"SARS-CoV-2 spike protein-mediated cell signaling in lung vascular cells","volume":"137","author":"Suzuki YJ","year":"2021","unstructured":"Suzuki YJ, Nikolaienko SI, Dibrova VA, et al.. SARS-CoV-2 spike protein-mediated cell signaling in lung vascular cells. Vascul Pharmacol. 2021, 137:106823. 10.1016\/j.vph.2020.106823","journal-title":"Vascul Pharmacol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.121.318902","article-title":"SARS-CoV-2 spike protein impairs endothelial function via downregulation of ACE 2","volume":"128","author":"Lei Y","year":"2021","unstructured":"Lei Y, Zhang J, Schiavon CR, et al.. SARS-CoV-2 spike protein impairs endothelial function via downregulation of ACE 2. Circ Res. 2021, 128:1323-6. 10.1161\/CIRCRESAHA.121.318902","journal-title":"Circ Res"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.118.10266","article-title":"Understanding angiotensin II type 1 receptor signaling in vascular pathophysiology","volume":"71","author":"Eguchi S","year":"2018","unstructured":"Eguchi S, Kawai T, Scalia R, Rizzo V. Understanding angiotensin II type 1 receptor signaling in vascular pathophysiology. Hypertension. 2018, 71:804-10. 10.1161\/HYPERTENSIONAHA.118.10266","journal-title":"Hypertension"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.2c03925","article-title":"Amyloidogenesis of SARS-CoV-2 spike protein","volume":"144","author":"Nystr\u00f6m S","year":"2022","unstructured":"Nystr\u00f6m S, Hammarstr\u00f6m P. Amyloidogenesis of SARS-CoV-2 spike protein. J Am Chem Soc. 2022, 144:8945-50. 10.1021\/jacs.2c03925","journal-title":"J Am Chem Soc"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.09.031","article-title":"Immune-mediated hepatitis with the Moderna vaccine, no longer a coincidence but confirmed","volume":"76","author":"Zin Tun GS","year":"2022","unstructured":"Zin Tun GS, Gleeson D, Al-Joudeh A, Dube A. Immune-mediated hepatitis with the Moderna vaccine, no longer a coincidence but confirmed. J Hepatol. 2022, 76:747-9. 10.1016\/j.jhep.2021.09.031","journal-title":"J Hepatol"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.03.040","article-title":"SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis","volume":"77","author":"Boettler T","year":"2022","unstructured":"Boettler T, Csernalabics B, Sali\u00e9 H, et al.. SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis. J Hepatol. 2022, 77:653-9. 10.1016\/j.jhep.2022.03.040","journal-title":"J Hepatol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2020.100051","article-title":"Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-19 via autoimmunity","volume":"3","author":"Lyons-Weiler J","year":"2020","unstructured":"Lyons-Weiler J. Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-19 via autoimmunity. J Transl Autoimmun. 2020, 3:100051. 10.1016\/j.jtauto.2020.100051","journal-title":"J Transl Autoimmun"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.617089","article-title":"Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: implications for autoimmune diseases","volume":"11","author":"Vojdani A","year":"2020","unstructured":"Vojdani A, Vojdani E, Kharrazian D. Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: implications for autoimmune diseases. Front Immunol. 2020, 11:617089. 10.3389\/fimmu.2020.617089","journal-title":"Front Immunol"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1080\/08916934.2023.2259123","article-title":"Autoimmune inflammatory reactions triggered by the COVID-19 genetic vaccines in terminally differentiated tissues","volume":"56","author":"Polykretis P","year":"2023","unstructured":"Polykretis P, Donzelli A, Lindsay JC, et al.. Autoimmune inflammatory reactions triggered by the COVID-19 genetic vaccines in terminally differentiated tissues. Autoimmunity. 2023, 56:2259123. 10.1080\/08916934.2023.2259123","journal-title":"Autoimmunity"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.103479","article-title":"The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory","volume":"24","author":"Ndeupen S","year":"2021","unstructured":"Ndeupen S, Qin Z, Jacobsen S, Bouteau A, Estanbouli H, Igy\u00e1rt\u00f3 BZ. The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience. 2021, 24:103479. 10.1016\/j.isci.2021.103479","journal-title":"iScience"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.108572","article-title":"mRNA COVID-19 vaccine elicits potent adaptive immune response without the acute inflammation of SARS-CoV-2 infection","volume":"26","author":"Ivanova EN","year":"2023","unstructured":"Ivanova EN, Shwetar J, Devlin JC, et al.. mRNA COVID-19 vaccine elicits potent adaptive immune response without the acute inflammation of SARS-CoV-2 infection. iScience. 2023, 26:108572. 10.1016\/j.isci.2023.108572","journal-title":"iScience"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109762","article-title":"The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses","volume":"255","author":"F\u00f6hse K","year":"2023","unstructured":"F\u00f6hse K, Geckin B, Zoodsma M, et al.. The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses. Clin Immunol. 2023, 255:109762. 10.1016\/j.clim.2023.109762","journal-title":"Clin Immunol"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.656700","article-title":"SARS-CoV-2 spike targets USP33-IRF9 axis via exosomal miR-148a to activate human microglia","volume":"12","author":"Mishra R","year":"2021","unstructured":"Mishra R, Banerjea AC. SARS-CoV-2 spike targets USP33-IRF9 axis via exosomal miR-148a to activate human microglia. Front Immunol. 2021, 12:656700. 10.3389\/fimmu.2021.656700","journal-title":"Front Immunol"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0228-3","article-title":"Basal cell carcinoma: PD-L1\/PD-1 checkpoint expression and tumor regression after PD-1 blockade","volume":"5","author":"Lipson EJ","year":"2017","unstructured":"Lipson EJ, Lilo MT, Ogurtsova A, et al.. Basal cell carcinoma: PD-L1\/PD-1 checkpoint expression and tumor regression after PD-1 blockade. J Immunother Cancer. 2017, 5:23. 10.1186\/s40425-017-0228-3","journal-title":"J Immunother Cancer"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2022-0787","article-title":"Increased PD-L1 surface expression on peripheral blood granulocytes and monocytes after vaccination with SARS-CoV2 mRNA or vector vaccine","volume":"61","author":"Loacker L","year":"2023","unstructured":"Loacker L, Kimpel J, B\u00e1nki Z, Schmidt CQ, Griesmacher A, Anliker M. Increased PD-L1 surface expression on peripheral blood granulocytes and monocytes after vaccination with SARS-CoV2 mRNA or vector vaccine. Clin Chem Lab Med. 2023, 61:e17-9. 10.1515\/cclm-2022-0787","journal-title":"Clin Chem Lab Med"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000661","article-title":"An immune evasion mechanism with IgG4 playing an essential role in cancer and implication for immunotherapy","volume":"8","author":"Wang H","year":"2020","unstructured":"Wang H, Xu Q, Zhao C, et al.. An immune evasion mechanism with IgG4 playing an essential role in cancer and implication for immunotherapy. J Immunother Cancer. 2020, 8:e000661. 10.1136\/jitc-2020-000661","journal-title":"J Immunother Cancer"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02652-2","article-title":"The risk of malignancy in patients with IgG4-related disease: a systematic review and meta-analysis","volume":"24","author":"Yu T","year":"2022","unstructured":"Yu T, Wu Y, Liu J, Zhuang Y, Jin X, Wang L. The risk of malignancy in patients with IgG4-related disease: a systematic review and meta-analysis. Arthritis Res Ther. 2022, 24:14. 10.1186\/s13075-021-02652-2","journal-title":"Arthritis Res Ther"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.ade2798","article-title":"Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination","volume":"8","author":"Irrgang P","year":"2023","unstructured":"Irrgang P, Gerling J, Kocher K, et al.. Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination. Sci Immunol. 2023, 8:10.1126\/sciimmunol.ade2798","journal-title":"Sci Immunol"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11050991","article-title":"IgG4 antibodies induced by repeated vaccination may generate immune tolerance to the SARS-CoV-2 spike protein","volume":"11","author":"Uversky VN","year":"2023","unstructured":"Uversky VN, Redwan EM, Makis W, Rubio-Casillas A. IgG4 antibodies induced by repeated vaccination may generate immune tolerance to the SARS-CoV-2 spike protein. Vaccines (Basel). 2023, 11:991. 10.3390\/vaccines11050991","journal-title":"Vaccines (Basel)"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.726960","article-title":"Induction of high levels of specific humoral and cellular responses to SARS-CoV-2 after the administration of COVID-19 mRNA vaccines requires several days","volume":"12","author":"Gil-Manso S","year":"2021","unstructured":"Gil-Manso S, Carbonell D, L\u00f3pez-Fern\u00e1ndez L, et al.. Induction of high levels of specific humoral and cellular responses to SARS-CoV-2 after the administration of COVID-19 mRNA vaccines requires several days. Front Immunol. 2021, 12:726960. 10.3389\/fimmu.2021.726960","journal-title":"Front Immunol"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9091013","article-title":"Varicella zoster virus reactivation following COVID-19 vaccination: a systematic review of case reports","volume":"9","author":"Katsikas Triantafyllidis K","year":"2021","unstructured":"Katsikas Triantafyllidis K, Giannos P, Mian IT, Kyrtsonis G, Kechagias KS. Varicella zoster virus reactivation following COVID-19 vaccination: a systematic review of case reports. Vaccines (Basel). 2021, 9:1013. 10.3390\/vaccines9091013","journal-title":"Vaccines (Basel)"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-021-02220-z","article-title":"SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus","volume":"4","author":"Chen J","year":"2021","unstructured":"Chen J, Dai L, Barrett L, James J, Plaisance-Bonstaff K, Post SR, Qin Z. SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus. Commun Biol. 2021, 4:682. 10.1038\/s42003-021-02220-z","journal-title":"Commun Biol"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/3191569","article-title":"Role of Epstein-Barr virus and human papilloma virus in the development of oropharyngeal cancer: a literature review","volume":"2022","author":"Migliaro M","year":"2022","unstructured":"Migliaro M, Massuh D, Infante MF, Brahm AM, San Mart\u00edn MT, Ortu\u00f1o D. Role of Epstein-Barr virus and human papilloma virus in the development of oropharyngeal cancer: a literature review. Int J Dent. 2022, 2022:10.1155\/2022\/3191569","journal-title":"Int J Dent"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061647","article-title":"Estrogen signaling and its potential as a target for therapy in ovarian cancer","volume":"12","author":"Langdon SP","year":"2020","unstructured":"Langdon SP, Herrington CS, Hollis RL, Gourley C. Estrogen signaling and its potential as a target for therapy in ovarian cancer. Cancers (Basel). 2020, 12:1647. 10.3390\/cancers12061647","journal-title":"Cancers (Basel)"},{"key":"ref79","article-title":"The functional role of estrogen receptor alpha (ER\u03b1) in AML; a new potential therapeutic target for the treatment of inv (16) and MLL-rearranged acute myeloid leukemia","author":"van Dijk AD","year":"2020","unstructured":"van Dijk AD. The functional role of estrogen receptor alpha (ER\u03b1) in AML; a new potential therapeutic target for the treatment of inv (16) and MLL-rearranged acute myeloid leukemia. University of Groningen, Groningen, Netherlands; 2020."},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118302","article-title":"Important roles of estrogen receptor alpha in tumor progression and anti-estrogen therapy of pancreatic ductal adenocarcinoma","volume":"260","author":"Xue J","year":"2020","unstructured":"Xue J, Yao Y, Yao Q, et al.. Important roles of estrogen receptor alpha in tumor progression and anti-estrogen therapy of pancreatic ductal adenocarcinoma. Life Sci. 2020, 260:118302. 10.1016\/j.lfs.2020.118302","journal-title":"Life Sci"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2021.105461","article-title":"Biologic and behavioral associations of estrogen receptor alpha positivity in head and neck squamous cell carcinoma","volume":"121","author":"Drake V","year":"2021","unstructured":"Drake V, Bigelow E, Fakhry C, et al.. Biologic and behavioral associations of estrogen receptor alpha positivity in head and neck squamous cell carcinoma. Oral Oncol. 2021, 121:105461. 10.1016\/j.oraloncology.2021.105461","journal-title":"Oral Oncol"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.15162","article-title":"Is there a role for sex hormone receptors in head-and-neck cancer? Links with HPV infection and prognosis","volume":"41","author":"DE Oliveira Neto CP","year":"2021","unstructured":"DE Oliveira Neto CP, Brito HO, DA Costa RM, Brito LM. Is there a role for sex hormone receptors in head-and-neck cancer? Links with HPV infection and prognosis. Anticancer Res. 2021, 41:3707-16. 10.21873\/anticanres.15162","journal-title":"Anticancer Res"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11030826","article-title":"The role of er\u03b1 and er\u03b2 in castration-resistant prostate cancer and current therapeutic approaches","volume":"11","author":"Jefferi NE","year":"2023","unstructured":"Jefferi NE, Shamhari A', Noor Azhar NK, et al.. The role of er\u03b1 and er\u03b2 in castration-resistant prostate cancer and current therapeutic approaches. Biomedicines. 2023, 11:10.3390\/biomedicines11030826","journal-title":"Biomedicines"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.add4150","article-title":"The SARS-CoV-2 spike protein binds and modulates estrogen receptors","volume":"8","author":"Solis O","year":"2022","unstructured":"Solis O, Beccari AR, Iaconis D, et al.. The SARS-CoV-2 spike protein binds and modulates estrogen receptors. Sci Adv. 2022, 8:eadd4150. 10.1126\/sciadv.add4150","journal-title":"Sci Adv"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2016.06.004","article-title":"Rapid steroid hormone actions via membrane receptors","volume":"1863","author":"Schwartz N","year":"2016","unstructured":"Schwartz N, Verma A, Bivens CB, Schwartz Z, Boyan BD. Rapid steroid hormone actions via membrane receptors. Biochim Biophys Acta. 2016, 1863:2289-98. 10.1016\/j.bbamcr.2016.06.004","journal-title":"Biochim Biophys Acta"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgq255","article-title":"Estrogen receptor \u03b1-mediated transcription induces cell cycle-dependent DNA double-strand breaks","volume":"32","author":"Williamson LM","year":"2011","unstructured":"Williamson LM, Lees-Miller SP. Estrogen receptor \u03b1-mediated transcription induces cell cycle-dependent DNA double-strand breaks. Carcinogenesis. 2011, 32:279-85. 10.1093\/carcin\/bgq255","journal-title":"Carcinogenesis"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1803177115","article-title":"BRCA1 ensures genome integrity by eliminating estrogen-induced pathological topoisomerase II-DNA complexes","volume":"115","author":"Sasanuma H","year":"2018","unstructured":"Sasanuma H, Tsuda M, Morimoto S, et al.. BRCA1 ensures genome integrity by eliminating estrogen-induced pathological topoisomerase II-DNA complexes. Proc Natl Acad Sci U S A. 2018, 115:E10642-51. 10.1073\/pnas.1803177115","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.3390\/genes13030391","article-title":"G-quadruplex matters in tissue-specific tumorigenesis by BRCA1 deficiency","volume":"13","author":"Kim S","year":"2022","unstructured":"Kim S, Hwang S. G-quadruplex matters in tissue-specific tumorigenesis by BRCA1 deficiency. Genes (Basel). 2022, 13:391. 10.3390\/genes13030391","journal-title":"Genes (Basel)"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.17548","article-title":"Co-transcriptional R-loops are the main cause of estrogen-induced DNA damage","volume":"5","author":"Stork CT","year":"2016","unstructured":"Stork CT, Bocek M, Crossley MP, et al.. Co-transcriptional R-loops are the main cause of estrogen-induced DNA damage. Elife. 2016, 5:e17548. 10.7554\/eLife.17548","journal-title":"Elife"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1073789","article-title":"Nuclear translocation of spike mRNA and protein is a novel feature of SARS-CoV-2","volume":"14","author":"Sattar S","year":"2023","unstructured":"Sattar S, Kabat J, Jerome K, Feldmann F, Bailey K, Mehedi M. Nuclear translocation of spike mRNA and protein is a novel feature of SARS-CoV-2. Front Microbiol. 2023, 14:1073789. 10.3389\/fmicb.2023.1073789","journal-title":"Front Microbiol"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100814","article-title":"S2 subunit of SARS-nCoV-2 interacts with tumor suppressor protein p53 and BRCA: an in silico study","volume":"13","author":"Singh N","year":"2020","unstructured":"Singh N, Bharara Singh A. S2 subunit of SARS-nCoV-2 interacts with tumor suppressor protein p53 and BRCA: an in silico study. Transl Oncol. 2020, 13:100814. 10.1016\/j.tranon.2020.100814","journal-title":"Transl Oncol"},{"key":"ref92","unstructured":"Force-facing our risk of cancer empowered. cancer risks associated with inherited mutations. (2023). Accessed: March 28, 2024: https:\/\/www.facingourrisk.org\/info\/hereditary-cancer-and-genetic-testing\/hereditary-cancer-genes-and-risk\/genes-by-na...."},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.27.480","article-title":"Human DNA glycosylases involved in the repair of oxidatively damaged DNA","volume":"27","author":"Ide H","year":"2004","unstructured":"Ide H, Kotera M. Human DNA glycosylases involved in the repair of oxidatively damaged DNA. Biol Pharm Bull. 2004, 27:480-5. 10.1248\/bpb.27.480","journal-title":"Biol Pharm Bull"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1016\/j.labinv.2022.100025","article-title":"Indoxyl sulfate promotes metastatic characteristics of ovarian cancer cells via aryl hydrocarbon receptor-mediated downregulation of the MAS receptor","volume":"103","author":"Saito S","year":"2023","unstructured":"Saito S, Koya Y, Kajiyama H, Yamashita M, Nawa A. Indoxyl sulfate promotes metastatic characteristics of ovarian cancer cells via aryl hydrocarbon receptor-mediated downregulation of the MAS receptor. Lab Invest. 2023, 103:100025. 10.1016\/j.labinv.2022.100025","journal-title":"Lab Invest"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2105968118","article-title":"Reverse-transcribed SARS-CoV-2 RNA can integrate into the genome of cultured human cells and can be expressed in patient-derived tissues","volume":"118","author":"Zhang L","year":"2021","unstructured":"Zhang L, Richards A, Barrasa MI, Hughes SH, Young RA, Jaenisch R. Reverse-transcribed SARS-CoV-2 RNA can integrate into the genome of cultured human cells and can be expressed in patient-derived tissues. Proc Natl Acad Sci U S A. 2021, 118:e2105968118. 10.1073\/pnas.2105968118","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.3390\/cimb44030073","article-title":"Intracellular reverse transcription of Pfizer BioNTech COVID-19 mRNA vaccine BNT162b2 in vitro in human liver cell line","volume":"44","author":"Ald\u00e9n M","year":"2022","unstructured":"Ald\u00e9n M, Olofsson Falla F, Yang D, Barghouth M, Luan C, Rasmussen M, De Marinis Y. Intracellular reverse transcription of Pfizer BioNTech COVID-19 mRNA vaccine BNT162b2 in vitro in human liver cell line. Curr Issues Mol Biol. 2022, 44:1115-26. 10.3390\/cimb44030073","journal-title":"Curr Issues Mol Biol"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2023.111015","article-title":"Potential health risks of mRNA-based vaccine therapy: a hypothesis","volume":"171","author":"Acevedo-Whitehouse K","year":"2023","unstructured":"Acevedo-Whitehouse K, Bruno R. Potential health risks of mRNA-based vaccine therapy: a hypothesis. Med Hypotheses. 2023, 171:111015. 10.1016\/j.mehy.2023.111015","journal-title":"Med Hypotheses"},{"key":"ref98","unstructured":"FDA. Guidance for industry: characterization and qualification of cell substrates and other biological materials used in the production of viral vaccines for infectious disease indications. (2010). Accessed: March 7, 2024: https:\/\/www.fda.gov\/media\/78428\/download."},{"key":"ref99","unstructured":"[Digital agency. e-gov: Laws and Regulations Search (Special approval) Article 14-3]. (2024). Accessed: March 28, 2024: https:\/\/elaws.e-gov.go.jp\/document?lawid=335AC0000000145."},{"key":"ref100","unstructured":"South Carolina Senate hearing - USC Professor Dr. Phillip Buckhaults. (2023). Accessed. March 7, 2024: https:\/\/jessicar.substack.com\/p\/south-carolina-senate-hearing-usc."},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.31219\/osf.io\/mjc97","article-title":"DNA fragments detected in monovalent and bivalent Pfizer\/BioNTech and Moderna modRNA COVID-19 vaccines from Ontario, Canada: exploratory dose response relationship with serious adverse events [PREPRINT]","author":"Speicher D","year":"2023","unstructured":"Speicher D, Rose J, Gutschi LM, Wiseman DM, McKernan K. DNA fragments detected in monovalent and bivalent Pfizer\/BioNTech and Moderna modRNA COVID-19 vaccines from Ontario, Canada: exploratory dose response relationship with serious adverse events [PREPRINT]. OST Preprint. 2023, 10.31219\/osf.io\/mjc97","journal-title":"OST Preprint"}],"updated-by":[{"DOI":"10.7759\/cureus.r143","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"record-id":"54398"},{"DOI":"10.7759\/cureus.x58","type":"expression_of_concern","label":"Expression of concern","source":"retraction-watch","updated":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"record-id":"54399"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/196275-increased-age-adjusted-cancer-mortality-after-the-third-mrna-lipid-nanoparticle-vaccine-dose-during-the-covid-19-pandemic-in-japan","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T23:11:07Z","timestamp":1712617867000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/196275-increased-age-adjusted-cancer-mortality-after-the-third-mrna-lipid-nanoparticle-vaccine-dose-during-the-covid-19-pandemic-in-japan"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,8]]},"references-count":101,"URL":"https:\/\/doi.org\/10.7759\/cureus.57860","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,8]]}}}